What is AgaMatrix?
Founded in 2001 and headquartered in Salem, New Hampshire, AgaMatrix specializes in the development, manufacturing, and marketing of advanced diagnostic technologies. The company distinguishes itself through the integration of blood glucose monitoring with sophisticated data management capabilities, leveraging both mobile and cloud-based platforms to improve patient outcomes. By bridging the gap between hardware diagnostics and digital health analytics, AgaMatrix serves a vital role in the chronic disease management market, providing healthcare providers and patients with actionable insights derived from real-time physiological data. Its market position is defined by a long-standing history of innovation in patient-centric diagnostic tools.
How much funding has AgaMatrix raised?
AgaMatrix has raised a total of $63.7M across 5 funding rounds:
Series A
$2.7M
Series B
$5M
Series C
$23.7M
Debt
$32M
Debt
$350K
Series A (2003): $2.7M with participation from Collaborative Fund and Tank Partners
Series B (2007): $5M, investors not publicly disclosed
Series C (2008): $23.7M supported by Noble International Ltd
Debt (2017): $32M featuring Prospect Capital Corporation
Debt (2020): $350K backed by PPP
Key Investors in AgaMatrix
Prospect Capital Corporation
A leading business development company that provides private debt and private equity to middle-market companies, focusing on long-term capital appreciation.
Noble International Ltd
An Aptar Pharma company specializing in patient adherence solutions, including the development of training devices and human factors services for the pharmaceutical industry.
Collaborative Fund
A venture capital firm that invests in companies that are pushing the world forward, with a strong focus on the intersection of technology and societal impact.
What's next for AgaMatrix?
Looking ahead, AgaMatrix is positioned to leverage its recent capital injection to further refine its digital health architecture. As the healthcare industry shifts toward value-based care and remote patient monitoring, the company's focus on cloud-integrated diagnostics is likely to see increased demand. Strategic priorities will likely include the expansion of its data management ecosystem and the enhancement of its mobile platform capabilities to support broader therapeutic areas. By maintaining its focus on high-fidelity diagnostic hardware coupled with robust software analytics, AgaMatrix is well-equipped to navigate the evolving regulatory landscape and capitalize on the growing intersection of medical devices and digital health services.
See full AgaMatrix company page
